Working… Menu
Trial record 5 of 1529 for:    child psychiatry

Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01368510
Recruitment Status : Unknown
Verified December 2014 by Joseph O'Neill, PhD, University of California, Los Angeles.
Recruitment status was:  Recruiting
First Posted : June 8, 2011
Last Update Posted : December 18, 2014
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Joseph O'Neill, PhD, University of California, Los Angeles

Brief Summary:
Even with the best available treatments for obsessive-compulsive disorder (OCD), most patients only partially recover and many patients do not respond at all. Such incomplete and inadequate response contributes to greater public health costs in terms of morbidity and patient care expenses. This study aims for a better understanding of abnormal brain chemistry in OCD and how it is affected by cognitive-behavioral therapy (CBT) in order to develop novel therapies and improve the success of existing therapies. The main hypothesis is that CBT will change levels of the excitatory neurotransmitter glutamate in OCD patients in a region of the brain involved in OCD known as the cingulate cortex.

Condition or disease Intervention/treatment Phase
Obsessive-Compulsive Disorder (OCD) Behavioral: Intensive Cognitive Behavioral Therapy (CBT) Behavioral: Waitlist Not Applicable

Detailed Description:

This study will characterize the neurochemical abnormalities in important brain circuits underlying obsessive-compulsive disorder (OCD) symptoms and the effects of cognitive-behavioral therapy (CBT). Identification of such metabolite biomarkers will provide an important foundation for translational clinical studies to maximize the ability of CBT to reduce symptoms and to design medications that target core features of the disease, which is particularly important for those who do not respond to, or have access to, CBT.

OCD is an often disabling and chronic psychiatric condition that affects approximately 2% of the world's population. Most patients respond only incompletely to current treatments and many do not respond at all. CBT, a form of psychotherapy, is one of the most effective treatments for OCD, yet its mechanism of action is not fully understood. The objective of this study is to use neuroimaging to understand how neurometabolite abnormalities in neural circuits relate to OCD symptoms, and how these are affected by CBT. In OCD, dysfunction is suspected in several subregions of the cingulate gyrus, a brain region involved in relevant neural circuits. This study will use magnetic resonance spectroscopic imaging (MRSI) to measure concentrations of brain metabolites, including glutamate (Glu), in the cingulate. Glu is an important excitatory neurotransmitter that is suspected to be disturbed in OCD. In this study, MRSI scans will be performed on 25 adult OCD patients before and after 4 weeks of daily CBT. They will be compared to 25 untreated healthy controls scanned 4 weeks apart. A third group of 25 OCD patients will be scanned before and after 4 weeks while on the waitlist, will then receive 4 weeks of CBT, and will be scanned a third time at its completion. The specific aims of this study are: 1) Determine if levels of the Glu in the "emotional" and "cognitive" subregions of the cingulate differ between OCD patients and controls; 2) Determine if Glu changes after CBT or waitlist in the OCD patients and if they change in the controls after simple passage of time; 3) Determine if there are relationships between Glu and clinical and neurocognitive symptoms of OCD before and after CBT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cognitive-Behavioral Therapy and Glutamate in Cingulate Gyrus in OCD
Study Start Date : July 2011
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: OCD Active CBT
Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
Behavioral: Intensive Cognitive Behavioral Therapy (CBT)
Nondrug psychotherapy administered daily 5 days/week for 4 weeks
Other Name: Exposure and Response Prevention (ERP)

Active Comparator: OCD Waitlist
Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
Behavioral: Intensive Cognitive Behavioral Therapy (CBT)
Nondrug psychotherapy administered daily 5 days/week for 4 weeks
Other Name: Exposure and Response Prevention (ERP)

Behavioral: Waitlist
Minimal contact waitlist weekly for 4 weeks

No Intervention: Healthy Control
Healthy control adults will be given no intervention.

Primary Outcome Measures :
  1. MRSI glutamate [ Time Frame: 4 weeks ]
    Regional concentration of glutamate in brain, as measured by magnetic resonance spectroscopic imaging (MRSI)

Secondary Outcome Measures :
  1. Y-BOCS [ Time Frame: 4 weeks ]
    Severity of core obsessive-compulsive clinical symptoms as measured with the Yale-Brown Obsessive-Compulsive Scale score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • meets DSM-IV-TR diagnostic criteria for OCD as primary (most severe) diagnosis based on Anxiety Disorders Interview Schedule (ADIS) Clinical Severity Rating
  • reported DSM-IV-TR-threshold OCD symptom onset age 18 or later
  • Yale-Brown Obsessive-Compulsive total score greater than or equal to 16
  • fluent English speaker
  • signed informed consent

Exclusion Criteria:

  • IQ of less than 80 on the Wechsler Abbreviated Scales of Intelligence
  • lifetime DSM-IV diagnosis of pervasive developmental disorder, mania, psychosis, conduct disorder, or substance dependence assessed through ADIS
  • current DSM-IV diagnosis of major depressive disorder if ADIS CSR rating is 4 or higher (severe) or attention-deficit hyperactivity disorder
  • primary compulsive hoarding
  • any changes (dose or agent) in psychotropic medication for OCD or other psychiatric condition within 12 weeks prior to enrollment
  • severe illness that requires immediate inpatient psychiatric intervention
  • any serious psychiatric, psychosocial, or neurological condition requiring immediate treatment other than that provided in the current study
  • any body metal (other than dental fillings), positive pregnancy test, or other MR scan contraindications
  • prior trial of CBT for OCD, regardless of outcome
  • medical conditions that affect cerebral metabolism (e.g., thyroid disorders or diabetes)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01368510

Layout table for location contacts
Contact: Jamie D Feusner, MD (310) 206-4951
Contact: Courtney Sheen (310) 206-0468

Layout table for location information
United States, California
UCLA Obsessive-Compulsive Disorder Intensive Treatment Program Recruiting
Los Angeles, California, United States, 90024
Principal Investigator: Joseph O'Neill, PhD         
Principal Investigator: Jamie D Feusner, MD         
Sponsors and Collaborators
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Joseph O'Neill, PhD UCLA Child Psychiatry

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joseph O'Neill, PhD, Prof Child Psychiatry, University of California, Los Angeles Identifier: NCT01368510     History of Changes
Other Study ID Numbers: R01MH085900 ( U.S. NIH Grant/Contract )
R01MH085900 ( U.S. NIH Grant/Contract )
First Posted: June 8, 2011    Key Record Dates
Last Update Posted: December 18, 2014
Last Verified: December 2014
Keywords provided by Joseph O'Neill, PhD, University of California, Los Angeles:
obsessive-compulsive disorder (OCD)
cognitive-behavioral therapy (CBT)
magnetic resonance spectroscopy (MRS)
cingulate gyrus
Additional relevant MeSH terms:
Layout table for MeSH terms
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Personality Disorders
Mental Disorders
Anxiety Disorders